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Abstract
Purpose: Adaptive planning is often needed in lung cancer proton therapy to account for geometrical
variations, such as tumor shrinkage and other anatomical changes. The purpose of this study is to
present our findings in adaptive radiotherapy for lung cancer using uniform scanning proton beams,
including clinical workflow, adaptation strategies and considerations, and toxicities.
Methods: We analyzed 165 lung patients treated using uniform scanning proton beams at our
center. Quality assurance (QA) plans were generated after repeated computerized tomography (CT)
scan to evaluate anatomic and dosimetric change during the course of treatment. Plan adaptation was
determined mutually by physicists and physicians after QA plan evaluation, based on several clinical and
practical considerations including potential clinical benefit and associated cost in plan adaption. Detailed
analysis was performed for all patients with a plan adaptation, including the type of anatomy change,
at which fraction the adaption was made, and the strategy for adaptation. Toxicities were compared
between patients with and without plan adaptation.
Results: In total, 32 adaptive plans were made for 31 patients out of 165 patients, with one patient
undergoing adaptive planning twice. Anatomy changes leading to plan adaptation included tumor
shrinkage (17), pleural effusion (3), patient weight loss (2), and tumor growth or other anatomy change
(9). The plan adaptation occurred at the 15th fraction on average and ranged from the 1st to 31st fraction.
Strategies of plan adaptation included range change only (18), re-planning with new patient-specific
hardware (9), and others (5). Most toxicities were Grade 1 or 2, with dermatitis the highest toxicity rate.
Conclusions: Adaptive planning is necessary in proton therapy to account for anatomy change and
its effect on proton penetration depth during the course of treatment. It is important to take practical
considerations into account and fully understand the limitations of plan adaptation process and tools
to make wise decision on adaptive planning. USPT is a safe treatment for lung cancer patients with no
Grade 4 toxicity.

Introduction
Lung cancer remains to be the leading cause of cancer death in the United States
with over 154,000 lung cancer deaths estimated in 2018 [1 https://www.cancer.org/
cancer/non-small-cell-lung-cancer/about/key-statistics.html]. Proton beam therapy
(PBT) has been increasingly used for lung cancer, mainly because of its dose advantage
over conventional radiation therapy such as 3D conformal radiation therapy (3DCRT)
and intensity modulated radiation therapy (IMRT), and the increased number of
proton therapy centers becoming available. Based on how a proton beam is spread
out laterally and in depth, there are three main types of proton delivery techniques:
passive scattering proton therapy (PSPT), uniform scanning proton therapy (USPT),
and pencil beam scanning (PBS) [1-3].
HTTPS://WWW.HEIGHPUBS.ORG
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Previous studies have shown that compared to 3D conformal or intensity modulated
photon radiation, proton beams can better spare the lung, esophagus, heart, cord,
and other normal tissues while delivering the same or higher dose to the treatment
target, potentially leading to better tumor control and less toxicity [4-12]. Using PSPT,
Chang et al. reported that the dose to normal tissues and the integral dose to patients
with non-small cell lung cancer (NSCLC) were signi icantly reduced compared to 3DCRT and IMRT [11]. Kadoya et al., reported that PSPT signi icantly reduced lung dose
compared to stereotactic body radiation therapy (SBRT) for Stage I non-small-cell lung
cancer [10]. For SBRT with a prescribed dose for 66 Gy, the mean dose, V5, V10, V15,
and V20 were 7.8 Gy, 32%, 21.8%, 15.3%, and 11.4% for SBRT, but reduced to 4.6 Gy,
13.2%, 11.4%, 10.1%, and 9.1% for proton therapy, respectively. In addition to less
dose to the lung, Hoppe et al. reported that PSPT delivered less dose (D0.1cc and D5cc)
to the heart, esophagus and bronchus compared to SBRT [9]. For locally advanced Stage
III NSCLC patients, Wu et al. found that proton beam therapy was feasible and would
spare lungs, heart and spinal cord better compared to 3DCRT[5]. Because of its less
proximal dose and better optimization capability, IMPT can further reduce doses to
normal tissues, such as the lung, spinal cord, heart, and esophagus, compared to PSPT
and IMRT for extensive Stage IIIB NSCLC, as reported by Zhang et al. [13]. Stuschke et
al., also reported that IMPT was advantageous in terms of lung sparing compared to
both Tomotherapy and IMRT [7]. The dosimetry of USPT for lung cancer was similar to
PSPT, as reported by Zheng [14].
While proton beams provide a superior dose distribution due to their inite ranges,
the dose advantage can be compromised due to range uncertainties and changes from
the daily setup variation and anatomical change. This is of particular concern for lung
cancer therapy since progressive anatomical changes such as tumor shrinkage and
positional changes are often observed (Toward Adaptive, 1st paragraph). Hui et al.,
found that inter-fractional motion and anatomic change could lead to a result of up to
8% reduction of CTV coverage and a mean 4.4 CGE maximum dose increase of spinal
cord [20]. Koey et al., reported that without adaptive planning, target coverage could
be dropped to below 60% for some lung cancer case undergoing proton therapy [21].
To account for the dose disturbance due to the anatomical changes, adaptive planning
is often required to ensure optimal target coverage and normal tissue sparing during
the whole course of proton therapy.
Uniform scanning proton therapy (USPT) has been used at our proton center for
lung cancer patient treatment. Its use in adaptive planning of lung cancer patients and
its toxicities has been rarely reported. The purpose of this study is to illustrate our
work low, strategies, and practical considerations in adaptive planning of lung cancers
using USPT. In addition, the acute and late toxicities for lung cancer patients treated at
our center were also analyzed.

Materials and Methods
Treatment techniques
Simulation: Each patient was simulated using GE CT scanner (Lightspeed 16,
Wisconsin) and an RPM system (Varian, Palt, CA) for motion monitoring. Patients
typically lied supine, were immobilized with a vacuum bag, which was on top of an
index ixed framing device (wing board), and had their arms up and hands holding the
pegs on the wing board. The patient was scanned at 2.5 mm slice thickness. If contrast
is used, one computerized tomography (CT) scan should be taken before the contrast
is injected in addition to one after the injection. The CT data with intravenous contrast
will be used primarily for target delineation, and the CT data set without contrast
will be used for dose calculation. Tumor motion was evaluated by physics team. If the
magnitude of motion was too big (e.g., larger than 1 cm), either motion management
would be applied, such as the use of compression belt, or conventional photon therapy
would be used for treatment instead of proton therapy.
Published: September 13, 2018
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Treatment planning: Based on the 4D CT scan, the internal gross target volume (IGTV)
was contoured on the maximum intensity pixel (MIP) images and expanded 7–10 mm
to generate the clinical target volume (CTV). The CTV was further expanded by 5 mm
to obtain the planning target volume (PTV). Treatment planning and dose calculation
were performed on the average CT, using the XiO TPS (Version 5.0, Elekta Inc., St. Louis,
MO). To account for the tissue density change in proton beam path at the presence of the
tumor motion, IGTV was overridden to a proton stopping power ratio of tumor tissue,
about 1.01 based on sampling of over 10 lung patients treated at our center. In addition,
a smearing of 10 mm was used in compensator calculation for all lung cancer treatment
planning. 2–4 ields were employed in a treatment plan. Target coverage and doses to
normal tissues such as spinal cord, heart and lung, were evaluated to optimize the beam
angle and beam weight for optimal dose distribution. Most patients were treated with 2
CGE (Cobalt Gray equivalent) per fraction for a total dose of from 60 to 74 CGE. A small
portion of patients were treated with hypo-fractionation, such as 10 CGE by 3 fractions,
10 CGE by 4 fractions, and 12.5 CGE by 4 fractions.
Treatment delivery. Each patient was treated using uniform scanning proton beams
exclusively at our center. The proton therapy unit was made by IBA (Louvain-La-Neuve,
Belgium). During the treatment, patients were set up using the same immobilization
device as CT simulation and positioned as closely as possible to simulation. Orthogonal
x-ray images were used to align and verify the patient positioning and setup every day
before treatment. Proton beam was delivered layer by layer with the deepest layer
delivered irst. The beam delivery time was typically 1 minute or less per beam, and the
total patient in room time was about half hour or less for both setup and beam delivery.
Adaptive planning
Adaptive treatment planning was performed to ensure optimal target coverage
and normal tissue sparing when patient anatomy or tumor motion changed during
the course of treatment for lung cancer patients. For each patient, repeated 4D CT
scanning was performed after patients received about 14 CGE, 30 CGE, and 50 CGE. The
new CT image set was registered to the initial CT data, using the VelocityAI software
system (Version 3.1.0, Varian Medical Systems, Palo Alto, CA). Contours were copied
from the initial CT to the new CT, and modi ied as needed. A quality assurance (QA)
plan was then generated by applying the same proton beams in the original plan to
the registered new CT dataset. Physicists and physicians would review the QA plan
and determine whether plan adaptation was needed based on several clinical and
practical considerations: the PTV coverage and normal tissue dose in the QA plan, the
dose deviation from the original plan, the number of fractions remained, and the effort
and cost to implement the adaptive plan (e.g., whether new hardware fabrication was
involved). If plan change was determined necessary, plan adaptation was applied by
either adjust proton ranges for certain beams, adjust beam weight, or replanning with
the newly repeated 4D CT. The adapted plan would be used to treat the patient as soon
as possible after necessary QA and hardware fabrication. The process of treatment,
QA CT, QA planning, and plan adaptation will be repeated until the patient complete
the treatment course. A clinical work low of the adaptive planning for lung cancer
treatment at our center is shown in igure 1.
Patients and toxicities
In total, we analyzed 165 patients that were treated at our proton therapy center.
Among them, 62% of patients were male and 28% female. 14% of patients had small
cell lung cancer, and 86% of patients had non-small cancer. The disease stage ranged
from stage IA to stage IV. The patients ranged from 49 to 91 years old, with a mean age
of 70.8 years old.
The toxicity data was obtained from the research database that was maintained by
the Proton Collaborative Group (PCG). Toxicity analysis was based on the 143 out of
Published: September 13, 2018
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165 patients who were enrolled in the PCG protocols. The patients undergoing adaptive
planning were manually identi ied and their toxicity data was analyzed separately for
comparison with patients without adaptive planning.

Results
Adaptive planning
In total 32 adaptive plans (19%) were made, with one patient experiencing plan
adaptation twice. The main reasons leading to plan adaptation include tumor shrinkage
(17), tumor growth (6), pleural effusion (3), weight loss (2), and others (3). The plan
adaptation strategies include range change only (18), range and modulation change
(3), range, modulation, and weight change (2), and replanning (9) (Figure 2).
The time when a plan adaptation was made ranged from the 1st fraction to 31st
fraction, with average of about 3 weeks from treatment start, i.e., at about the 17th
fraction. The time from QA CT was scanned to the 1st treatment with the adaptive plan
ranged from 1 to 2 days when no new hardware was needed, and 3-4 days when it was
re-planned with new hardware, i.e., apertures and/or range compensators.
Toxicities
The toxicity rate for lung cancer patients with and without adaptive planning is
shown in igure 3. Dermatitis is the most common toxicity for both patients with and
without adaptive planning, followed by esophagitis, hoarseness and constipation for
patient with adaptive planning, and fatigue, cough, esophagitis for patients without
adaptive planning. The majority of toxicities are Grade 1 and Grade 2. Grade 3
occurrence was very rare Grade 3 and no Grade 4 toxicity was found.

Figure 1: A clinical workflow of adaptive planning for lung cancer treatment using uniform scanning proton therapy
(from Zheng [15]).

a) b)

Figure 2: An example of plan adaptation by increasing proton range. Patient developed fluid buildup at the 25th fraction,
leading to target under coverage for the QA plan (a). Proton range was increased by 2.2 cm in the adjusted plan (b).
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a)

b)
Figure 3: Toxicity rate for lung cancer patients treated with USPT. a) with adaptive planning. b) without adaptive
planning.

Discussion
In this study, we presented our indings on adaptive planning for lung cancer
therapy using USPT, including clinical work low, practical considerations and
toxicities. To our knowledge, the study is the irst to report such indings on adaptive
lung cancer treatment using USPT. About 19% of patients in this study underwent
adaptive planning using USPT, which is similar to what was reported using other
proton therapy techniques. For lung cancer treatment with PSPT, Koay et al. reported
that 20.5% of lung cancer patients underwent adaptive planning [16]. For PBS or
IMPT, Chang et al. reported that 26.5% patients were re-planed [17]. Please note that
the strategy used for plan adaptation depends largely on the institutional practice and
the beam delivery technique used for lung cancer treatment. Re-planning based on the
new CT data is a straightforward way commonly used for adaptive treatment for both
PSPT and PBS and can also be used for USPT. However, USPT delivers a homogeneous
dose to target region, and the proton range can be easily adjusted, so we can adapt
the plan by simply adjusting the proton range (and/or modulation width) to maintain
similar dose coverage due to anatomy change for certain cases.
The criteria on whether to adapt a plan can vary from institution to institution as
well as the individual physicist or physician who reviews the QA plan. At our center,
several factors were considered to decide a plan change: 1) whether the target dose
coverage and normal tissue dose meet the dose constraints; 2) how much the changes
are in target dose coverage and normal tissue dose between the QA plan and initial
plan; 3) how many fractions are left; 4) how easily and how quickly to adapt a plan,
e.g., whether it is a simple range/modulation change or a replan that needs new
hardware fabrication; and 5) what the performance status and treatment goal of the
patient and potential clinical impact for the patient are. While plan adaptation would
typically improve dosimetric distribution of a treatment plan, it is also associated to
certain costs, such as the hardware fabrication, extra efforts to make plan adaptation,
Published: September 13, 2018
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and potential treatment errors and safety concern associated with any plan change.
Therefore, it is our recommendation to consider other clinical and practical factors
in addition to DVH endpoints when we decide on whether to make a plan adaptation.
It is critical to fully understand the limitations in plan adaptation process and
software tools when evaluating a QA plan. The patient setup in QA CT could be different
from the initial CT scan, the image registration software may be not accurate, and the
QA plan generation may be incorrect. For example, our treatment plan system does
not account for the patient pitch and roll when a QA plan is applied to the new CT
data. Also, the beam isocenter for the QA plan was manually placed by a dosimetrist
based on image registration, which could be incorrectly placed, especially when
different isocenters were used for an initial and boost plan. These limitations or errors
in the image registration and QA plan process could result in arti icial dose deviation
unrelated to anatomy change, leading to unnecessary or incorrect plan adaptation.
Therefore, our practice is to always analyze the anatomy change and the correlation
between the dose change and anatomy change when we evaluate the QA plan and its
dose distribution. If noticeable dose change is in the QA plan but not correlated patient
anatomy/motion change or setup variation, it is likely that the dose change is arti icial
as a result of software limitations or human errors, and further investigation should
be warranted.
The top three toxicities for lung cancer therapy using USPT are dermatitis,
esophagus, and fatigue, and no Grade 4 toxicity was found in our study. These indings
are similar to those for patients treated using PSPT [16,18]. Pneumonitis was rare
among the patients in the study; however, it was not entered in the PCG database,
therefore not included in our toxicity analysis. Overall, we believe USPT is an effective
and safe treatment for lung cancer patients.
Currently, of line adaption has been used at our center and most other proton centers,
mainly because of lack of in room CT imaging, the long turnaround of manufacturing
patient speci ic device such as apertures and compensators, and lack of better tools
on QA plan generation and dose accumulation. However, pencil beam scanning has
been a mainstream in newly constructed proton centers, in room cone beam CT or
CT on rails are becoming available [12,15,19], and better tools are being developed
in image registration, dose accumulation, and plan adaptation. These advancements
would make online adaptation for proton therapy possible in the future.

Conclusion
In conclusion, USPT is a safe treatment for lung cancer patients. Adaptive planning
is necessary in proton therapy to account for anatomy change and its effect on proton
penetration depth during the course of treatment. It is important to take practical
considerations into account and fully understand the limitations of plan adaptation
process and tools to make wise decision on adaptive planning.
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